| scholarly article | Q13442814 |
| P356 | DOI | 10.1200/JCO.2000.18.3.547 |
| P698 | PubMed publication ID | 10653870 |
| P2093 | author name string | S Murphy | |
| F J Giles | |||
| H M Kantarjian | |||
| M Andreeff | |||
| T L Smith | |||
| C Koller | |||
| E J Freireich | |||
| M J Keating | |||
| S O'Brien | |||
| C S Ha | |||
| J Cortes | |||
| S Pierce | |||
| M Beran | |||
| Y Huh | |||
| P433 | issue | 3 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | adult acute lymphocytic leukemia | Q18556896 |
| acute lymphocytic leukemia | Q180664 | ||
| P304 | page(s) | 547-561 | |
| P577 | publication date | 2000-02-01 | |
| P1433 | published in | Journal of Clinical Oncology | Q400292 |
| P1476 | title | Results of treatment with hyper-CVAD, a dose-intensive regimen, in adult acute lymphocytic leukemia | |
| P478 | volume | 18 |
| Q35752048 | A Phase I/II Study of the mTOR Inhibitor Everolimus in Combination with HyperCVAD Chemotherapy in Patients with Relapsed/Refractory Acute Lymphoblastic Leukemia |
| Q37097719 | A Safety and Efficacy Study of Medium-Dose Etoposide, Cyclophosphamide and Total Body Irradiation Conditioning Before Allogeneic Stem Cell Transplantation for Acute Lymphoblastic Leukemia |
| Q37683288 | A randomized controlled trial of an intensive insulin regimen in patients with hyperglycemic acute lymphoblastic leukemia |
| Q44622623 | A randomized trial of induction therapy (daunorubicin, vincristine, prednisone versus daunorubicin, vincristine, prednisone, cytarabine and 6-thioguanine) in adult acute lymphoblastic leukemia with long-term follow-up: an Eastern Cooperative Oncolog |
| Q33419224 | A retrospective study of venous thromboembolism in acute leukemia patients treated at the University of Texas MD Anderson Cancer Center |
| Q40575613 | A single, high dose of idarubicin combined with cytarabine as induction therapy for adult patients with recurrent or refractory acute lymphoblastic leukemia |
| Q33378551 | A variant transcript, e1a3, of the minor BCR-ABL fusion gene in acute lymphoblastic leukemia: case report and review of the literature |
| Q33185818 | Aberrant DNA methylation in pediatric patients with acute lymphocytic leukemia |
| Q42237269 | Abnormal immunophenotype provides a key diagnostic marker: a report of 29 cases of de novo aggressive natural killer cell leukemia |
| Q43255274 | Achievement of complete donor-type chimerism and remission with dasatinib in Philadelphia chromosome-positive ALL relapsing after allogeneic transplantation. |
| Q90000799 | Activated stromal cells transfer mitochondria to rescue acute lymphoblastic leukemia cells from oxidative stress |
| Q51866966 | Active therapy and models of care for adolescents and young adults with cancer. |
| Q91790782 | Acute Lymphoblastic Leukemia Presenting Initially as Spinal Cord Compression: When Chemotherapy Alone Is Enough |
| Q92311313 | Acute Lymphoblastic Leukemia in Routine Practice: A Turkish Multicenter Study |
| Q35894965 | Acute lymphoblastic leukaemia in elderly patients: biological characteristics and therapeutic approaches |
| Q39420160 | Acute lymphoblastic leukemia experience: epidemiology and outcome of two different regimens |
| Q84122241 | Acute lymphoblastic leukemia in adolescents and young adults |
| Q35331684 | Acute lymphoblastic leukemia in elderly patients: a single institution's experience |
| Q37575938 | Acute lymphoblastic leukemia relapsing after first-line pediatric-inspired therapy: a retrospective GRAALL study |
| Q39406969 | Acute lymphoblastic leukemia: a comprehensive review and 2017 update |
| Q34123864 | Adult acute lymphocytic leukemia study testing chemotherapy and autologous and allogeneic transplantation. A follow-up report of the French protocol LALA 87. |
| Q34186588 | Adult acute lymphocytic leukemia. Future research directions |
| Q73369243 | Adult acute lymphocytic leukemia. Introduction and questions related to current programs |
| Q42947144 | Adults with acute lymphoblastic leukemia and translocation (1;19) abnormality have a favorable outcome with hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone alternating with methotrexate and high-dose cytarabine chemot |
| Q35058707 | Advanced-phase chronic myeloid leukemia |
| Q38685482 | Allogeneic Hematopoietic Stem Cell Transplantation with Myeloablative Conditioning Is Associated with Favorable Outcomes in Mixed Phenotype Acute Leukemia |
| Q57918815 | Allogeneic hematopoietic stem cell transplantation as part of postremission therapy improves survival for adult patients with high-risk acute lymphoblastic leukemia |
| Q79235598 | Allogeneic stem cell transplantation improves the outcome of adults with t(1;19)/E2A-PBX1 and t(4;11)/MLL-AF4 positive B-cell acute lymphoblastic leukemia: results of the prospective multicenter LALA-94 study |
| Q86946523 | Allogeneic stem cell transplantation using lymphoablative rather than myeloablative conditioning regimen for relapsed or refractory lymphomas |
| Q37107866 | Allogeneic transplantation for ALL in adults |
| Q36616349 | An analysis of the utilisation of chemoprophylaxis against Pneumocystis jirovecii pneumonia in patients with malignancy receiving corticosteroid therapy at a cancer hospital |
| Q45971930 | An effective reinduction regimen for first relapse of adult acute lymphoblastic leukemia. |
| Q43762000 | Analysis of 20-year follow-up study of LVP regimen for adult acute lymphoblastic leukemia |
| Q42634946 | Anthracycline dose intensification in adult acute lymphoblastic leukemia: lack of benefit in the context of the fractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone regimen |
| Q35848108 | Antigen-specific T-cell memory is preserved in children treated for acute lymphoblastic leukemia |
| Q92479171 | Approach to the Adult Acute Lymphoblastic Leukemia Patient |
| Q37738613 | Approaches to treatment for acute lymphoblastic leukemia in adolescents and young adults |
| Q36761302 | Association Between Younger Age and Targetable Genomic Alterations and Prognosis in Non-Small-Cell Lung Cancer |
| Q33747668 | Augmented and standard Berlin-Frankfurt-Munster chemotherapy for treatment of adult acute lymphoblastic leukemia |
| Q34186571 | Autologous stem cell transplantation for acute lymphocytic leukemia in adults |
| Q81632630 | Autologous stem cell transplantation in adults with acute lymphoblastic leukemia in first complete remission: analysis of the LALA-85, -87 and -94 trials |
| Q34376447 | B Lymphoblastic Lymphoma Presenting as a Tumor of the Nasopharynx in an Adult Patient |
| Q26784116 | Best Practices in Adolescent and Young Adult Patients with Acute Lymphoblastic Leukemia: A Focus on Asparaginase |
| Q37048373 | Bilateral Facial Nerve Palsy in Acute B Cell Lymphoblastic Leukemia: A Case Report and Review of the Literature |
| Q89906725 | Blinatumomab for the Treatment of Adult B-Cell Acute Lymphoblastic Leukemia: Toward a New Era of Targeted Immunotherapy |
| Q39796888 | Blinatumomab treatment of older adults with relapsed/refractory B-precursor acute lymphoblastic leukemia: Results from 2 phase 2 studies |
| Q46567838 | Breakthrough disseminated Scedosporium prolificans infection in a patient with relapsed leukaemia on prolonged voriconazole followed by posaconazole prophylaxis |
| Q33336403 | Burkitt's acute lymphocytic leukemia (L3ALL) in adults |
| Q34696338 | Burkitt's and Burkitt-like lymphoma. |
| Q35089339 | Burkitt's leukemia with precursor B-cell immunophenotype and atypical morphology (atypical Burkitt's leukemia/lymphoma): case report and review of literature |
| Q55193924 | CD19 CAR-T cell therapy for relapsed/refractory acute lymphoblastic leukemia: factors affecting toxicities and long-term efficacies. |
| Q29620607 | CD19-targeted T cells rapidly induce molecular remissions in adults with chemotherapy-refractory acute lymphoblastic leukemia |
| Q43991377 | CD56 expression predicts occurrence of CNS disease in acute lymphoblastic leukemia |
| Q33585849 | Central nervous system disease in hematologic malignancies: historical perspective and practical applications |
| Q35848955 | Central nervous system involvement in adult acute lymphoblastic leukemia at diagnosis: results from the international ALL trial MRC UKALL XII/ECOG E2993 |
| Q38269513 | Central nervous system involvement in adult acute lymphoblastic leukemia: diagnostic tools, prophylaxis, and therapy. |
| Q34186578 | Central nervous system involvement in adult acute lymphocytic leukemia |
| Q34102628 | Central nervous system prophylaxis in adults with acute lymphoblastic leukemia: current and emerging therapies |
| Q40658607 | Central nervous system relapse in adults with acute lymphoblastic leukemia |
| Q35136510 | Central nervous system relapse in adults with acute lymphoblastic leukemia after allogeneic hematopoietic stem cell transplantation |
| Q40817732 | Change in prognostic factors |
| Q34131844 | Chemoimmunotherapy with a modified hyper-CVAD and rituximab regimen improves outcome in de novo Philadelphia chromosome-negative precursor B-lineage acute lymphoblastic leukemia |
| Q35111716 | Clinical Applications of BCR-ABL Molecular Testing in Acute Leukemia |
| Q44279410 | Clinical activity of arsenic trioxide in Burkitt-like lymphoma |
| Q37253036 | Clinical consequences of hyperglycemia during remission induction therapy for pediatric acute lymphoblastic leukemia. |
| Q46611126 | Clinical effect of imatinib added to intensive combination chemotherapy for newly diagnosed Philadelphia chromosome-positive acute lymphoblastic leukemia |
| Q37738454 | Clinical manifestations and treatment of newly diagnosed acute lymphoblastic leukemia in adults |
| Q35024453 | Colony-stimulating factors for the management of neutropenia in cancer patients |
| Q43921031 | Comparison of two different schedules of granulocyte-colony-stimulating factor during treatment for acute lymphocytic leukemia with a hyper-CVAD (cyclophosphamide, doxorubicin, vincristine, and dexamethasone) regimen |
| Q37129564 | Complete remission after single agent blinatumomab in a patient with pre-B acute lymphoid leukemia relapsed and refractory to three prior regimens: hyperCVAD, high dose cytarabine mitoxantrone and CLAG. |
| Q36905115 | Comprehensive craniospinal radiation for controlling central nervous system leukemia |
| Q33587563 | Concurrent intensive chemotherapy and imatinib before and after stem cell transplantation in newly diagnosed Philadelphia chromosome-positive acute lymphoblastic leukemia. Final results of the CSTIBES02 trial |
| Q39093994 | Costo- Efectividad Del Uso Profiláctico Del Factor Estimulante De Colonias De Granulocitos En Adultos Con Leucemia Linfoblástica Aguda en Colombia |
| Q41773785 | Cytarabine Induced Acute Cerebellar Syndrome during Hyper-CVAD Treatment for B-Cell Acute Lymphoblastic Leukemia |
| Q34304230 | Cytogenetics in acute leukemia |
| Q80587777 | Death during induction therapy and first remission of acute leukemia in childhood: the St. Jude experience |
| Q92158098 | Diagnostic and treatment of adult Philadelphia chromosome-positive acute lymphoblastic leukemia |
| Q40591760 | Differential impact of minimal residual disease negativity according to the salvage status in patients with relapsed/refractory B-cell acute lymphoblastic leukemia |
| Q36059702 | Differential impact of structurally different anti-diabetic drugs on proliferation and chemosensitivity of acute lymphoblastic leukemia cells |
| Q33790257 | Dorsal column myelopathy following intrathecal chemotherapy for acute lymphoblastic leukemia |
| Q48136104 | Effectiveness of modified hyper-CVAD chemotherapy regimen in the treatment of adult acute lymphoblastic leukemia: a retrospective experience. |
| Q35740894 | Emerging pharmacotherapies for adult patients with acute lymphoblastic leukemia |
| Q37355967 | Epigenetics of acute lymphocytic leukemia |
| Q37572226 | Epoetin alpha decreases the number of erythrocyte transfusions in patients with acute lymphoblastic leukemia, lymphoblastic lymphoma, and Burkitt leukemia/lymphoma: results of a randomized clinical trial |
| Q37828067 | Epstein-Barr virus positive anaplastic large cell lymphoma: myth or reality? |
| Q41009415 | Evaluation of allogeneic transplantation in first or later minimal residual disease - negative remission following adult-inspired therapy for acute lymphoblastic leukemia |
| Q52562478 | Fibroblast Growth Factor 23-Induced Hypophosphatemia in Acute Leukemia. |
| Q35571035 | Final report of a phase II study of imatinib mesylate with hyper-CVAD for the front-line treatment of adult patients with Philadelphia chromosome-positive acute lymphoblastic leukemia |
| Q44375010 | Fractionated cyclophosphamide, vincristine, liposomal daunorubicin, and dexamethasone plus rituximab and granulocyte-macrophage-colony stimulating factor (GM-CSF) alternating with methotrexate and cytarabine plus rituximab and GM-CSF in patients wit |
| Q37369929 | Gene polymorphisms in folate metabolizing enzymes in adult acute lymphoblastic leukemia: effects on methotrexate-related toxicity and survival. |
| Q37625289 | HCVAD plus imatinib or dasatinib in lymphoid blastic phase chronic myeloid leukemia |
| Q40201466 | HDM4 (HDMX) is widely expressed in adult pre-B acute lymphoblastic leukemia and is a potential therapeutic target |
| Q57045402 | Hematopoietic Stem Cell Transplantation in the Era of Engineered Cell Therapy |
| Q36216252 | High curability via intensive reinduction chemotherapy and stem cell transplantation in young adults with relapsed acute lymphoblastic leukemia in Sweden 2003-2007. |
| Q36765731 | High expression of ID family and IGJ genes signature as predictor of low induction treatment response and worst survival in adult Hispanic patients with B-acute lymphoblastic leukemia |
| Q34186605 | High-dose anthracycline induction in adult acute lymphocytic leukemia |
| Q40044204 | High-dose methotrexate therapy significantly improved survival of adult acute lymphoblastic leukemia: A phase III study by JALSG. |
| Q28087589 | How I treat acute lymphoblastic leukemia in older adolescents and young adults |
| Q42414994 | Hydronephrosis Resulting from Bilateral Ureteral Stenosis: A Late Complication of Polyoma BK Virus Cystitis? |
| Q33341768 | Hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone and highly active antiretroviral therapy for patients with acquired immunodeficiency syndrome-related Burkitt lymphoma/leukemia |
| Q47165422 | Hypoalbuminemia is significantly associated with increased clearance time of high dose methotrexate in patients being treated for lymphoma or leukemia. |
| Q41960423 | Hypoglycemia associated with L-asparaginase in acute lymphoblastic leukemia treatment: a case report |
| Q47856397 | Imaging findings of childhood B-cell lymphoblastic lymphoma in the mental region: a case report |
| Q58414406 | Imatinib compared with chemotherapy as front-line treatment of elderly patients with Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ALL) |
| Q46661642 | Imatinib interim therapy between chemotherapeutic cycles and in vivo purging prior to autologous stem cell transplantation, followed by maintenance therapy is a feasible treatment strategy in Philadelphia chromosome-positive acute lymphoblastic leuk |
| Q33736847 | Impact of Aberrant Myeloid Antigen Expression on Outcomes of Patients with T-cell Acute Lymphoblastic Leukemia |
| Q37627410 | Impact of aberrant DNA methylation patterns including CYP1B1 methylation in adolescents and young adults with acute lymphocytic leukemia |
| Q36478476 | Impact of cytogenetics on the outcome of adult acute lymphoblastic leukemia: results of Southwest Oncology Group 9400 study |
| Q37086251 | Impact of cytomegalovirus reactivation on relapse and survival in patients with acute leukemia who received allogeneic hematopoietic stem cell transplantation in first remission |
| Q41472241 | Improved survival in adult patients with acute lymphoblastic leukemia in the Netherlands: a population-based study on treatment, trial participation and survival |
| Q35563658 | Incidence of and risk factors for involvement of the central nervous system in acute myeloid leukemia |
| Q33583302 | Indian Council of Medical Research Consensus Document for the Management of Non-Hodgkin's Lymphoma (High Grade). |
| Q44047915 | Induction therapy by frequent administration of doxorubicin with four other drugs, followed by intensive consolidation and maintenance therapy for adult acute lymphoblastic leukemia: the JALSG-ALL93 study |
| Q34186563 | Induction therapy of adult acute lymphocytic leukemia without the use of vincristine or prednisone |
| Q43476031 | Induction therapy using the MRC UKALLXII/ECOG E2993 protocol in Chinese adults with acute lymphoblastic leukemia |
| Q49905062 | Inotuzumab ozogamicin in combination with low-intensity chemotherapy for older patients with Philadelphia chromosome-negative acute lymphoblastic leukaemia: a single-arm, phase 2 study |
| Q34123842 | Insights into the biologic and molecular abnormalities in adult acute lymphocytic leukemia |
| Q38566744 | L-asparaginase and venous thromboembolism in acute lymphocytic leukemia |
| Q26738640 | L-asparaginase in the treatment of patients with acute lymphoblastic leukemia |
| Q37311985 | L-asparaginase-induced abnormality in plasma glucose level in patients of acute lymphoblastic leukemia admitted to a tertiary care hospital of Odisha |
| Q73873529 | Large granular lymphocyte leukemia and natural killer cell leukemia/lymphomas |
| Q49210894 | Lesions of the central nervous system in leukemia: Pathological and magnetic resonance imaging features at presentation in 14 patients |
| Q35989742 | Leukemia and the nervous system |
| Q80190985 | Leukemias and lymphomas: treatment and prophylaxis of the central nervous system |
| Q36282157 | Leukemic and lymphomatous meningitis: incidence, prognosis and treatment |
| Q64041671 | Limited efficacy of high-dose methotrexate in patients with neurolymphomatosis |
| Q44356040 | Lineage specific treatment of adult patients with acute lymphoblastic leukemia in first remission with anti-B4-blocked ricin or high-dose cytarabine: Cancer and Leukemia Group B Study 9311. |
| Q79829825 | Long-term follow-up of 14 patients with philadelphia chromosome-positive acute lymphoblastic leukemia following autologous bone marrow transplantation in first complete remission |
| Q77378759 | Long-term follow-up of patients with newly diagnosed adult acute lymphoblastic leukemia: a single institution experience of 378 consecutive patients over a 21-year period |
| Q80853383 | Long-term follow-up results of hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone (Hyper-CVAD), a dose-intensive regimen, in adult acute lymphocytic leukemia |
| Q43615614 | Long-term outcome of adult acute lymphoblastic leukemia in Lebanon: a single institution experience from the American University of Beirut |
| Q34186596 | Lymphoblastic lymphoma |
| Q57301411 | Management of older adults with acute lymphoblastic leukemia: challenges & current approaches |
| Q36629939 | Marqibo® (vincristine sulfate liposome injection) improves the pharmacokinetics and pharmacodynamics of vincristine |
| Q33566853 | Metabolic interrogation as a tool to optimize chemotherapeutic regimens. |
| Q42084832 | MicroRNA181a Is Overexpressed in T-Cell Leukemia/Lymphoma and Related to Chemoresistance |
| Q36781942 | Minimal residual disease assessed by multi-parameter flow cytometry is highly prognostic in adult patients with acute lymphoblastic leukaemia |
| Q42328093 | Minimal residual disease detection in Tunisian B-acute lymphoblastic leukemia based on immunoglobulin gene rearrangements |
| Q39400599 | Multi-center analysis of the effect of T-cell acute lymphoblastic leukemia subtype and minimal residual disease on allogeneic stem cell transplantation outcomes |
| Q35205559 | Myelopathy following intrathecal chemotherapy in adults: a single institution experience |
| Q40676167 | N-(4-Hydroxylphenyl)retinamide (fenretinide, 4-HPR), a retinoid compound with antileukemic and proapoptotic activity in acute lymphoblastic leukemia (ALL). |
| Q39147519 | Neurological Complications of the Leukemias Across the Ages |
| Q37836938 | New developments in the treatment of chronic myeloid leukemia and Philadelphia-positive acute lymphoblastic leukemia |
| Q46127676 | Nilotinib restores long-term full-donor chimerism in Ph-positive acute lymphoblastic leukemia relapsed after allogeneic transplantation. |
| Q37363925 | Novel Brentuximab Vedotin Combination Therapies Show Promising Activity in Highly Refractory CD30+ Non-Hodgkin Lymphoma: A Case Series and Review of the Literature. |
| Q38094099 | Novel therapeutic strategies in adult acute lymphoblastic leukemia--a focus on emerging monoclonal antibodies |
| Q34619129 | Novel therapies for relapsed acute lymphoblastic leukemia |
| Q34995983 | Older adolescents with cancer in North America deficits in outcome and research |
| Q36285964 | On the TRAIL of a new therapy for leukemia. |
| Q91634793 | Optimizing the use of the hyperCVAD regimen: Clinical vignettes and practical management |
| Q54342246 | Outcome after HSCT in Philadelphia chromosome positive acute lymphoblastic leukemia in Sweden: a population-based study. |
| Q93112971 | Outcome of Philadelphia Positive Acute Lymphoblastic Leukemia With or Without Allogeneic Stem Cell Transplantation in a Retrospective Study |
| Q34959054 | Outcome of adult acute lymphoblastic leukemia in South East of iran (zahedan). |
| Q50585551 | Outcome of allogeneic bone marrow transplantation from unrelated donors for adult Philadelphia chromosome-negative acute lymphocytic leukemia in first complete-remission. |
| Q94590363 | Outcome of donor lymphocyte infusion for fall in chimerism after hematopoietic stem cell transplant |
| Q82284200 | Outcome of medium-dose VP-16/CY/TBI superior to CY/TBI as a conditioning regimen for allogeneic stem cell transplantation in adult patients with acute lymphoblastic leukemia |
| Q50867633 | Outcome of patients with acute lymphoblastic leukemia (ALL) following induction therapy with a modified (pulsed dexamethasone rather than continuous prednisone) UKALL XII/ECOG E2993 protocol at Tawam Hospital, United Arab Emirates (UAE). |
| Q80568663 | Outcome of treatment after first relapse in adults with acute lymphoblastic leukemia initially treated by the LALA-94 trial |
| Q34300854 | Outcomes in older adults with acute lymphoblastic leukaemia (ALL): results from the international MRC UKALL XII/ECOG2993 trial |
| Q34018599 | Outcomes of patients with Burkitt lymphoma older than age 40 treated with intensive chemotherapeutic regimens |
| Q85241544 | Outcomes of second allogeneic hematopoietic stem cell transplantation for patients with acute lymphoblastic leukemia |
| Q35102183 | Perspectives on the treatment of chronic phase and advanced phase CML and Philadelphia chromosome positive ALL(1). |
| Q37080458 | Phase I/II trial of nanomolecular liposomal annamycin in adult patients with relapsed/refractory acute lymphoblastic leukemia |
| Q73499748 | Phase II study of single agent paclitaxel in adult patients with relapsed acute lymphocytic leukemia |
| Q81581465 | Phase II study of sphingosomal vincristine in patients with recurrent or refractory adult acute lymphocytic leukemia |
| Q37862648 | Philadelphia chromosome-positive acute lymphoblastic leukemia: current treatment and future perspectives |
| Q36562207 | Philadelphia chromosome-positive acute lymphoblastic leukemia: impact of imatinib treatment on remission induction and allogeneic stem cell transplantation |
| Q36824335 | Plasmablastic lymphoma of the maxillary sinus in an HIV-negative patient: a case report and literature review |
| Q90929187 | Polo-like kinases and acute leukemia |
| Q42019868 | Poor Response to Standard Chemotherapy in Early T-precursor (ETP)-ALL: A Subtype of T-ALL Associated with Unfavourable Outcome: A Brief Report |
| Q40208523 | Primary B-lymphoblastic lymphoma of gallbladder involving mandibular bone |
| Q37265645 | Primary lymphoblastic B-cell lymphoma of the stomach: a case report |
| Q92887039 | Prognostic and predictive value of a microRNA signature in adults with T-cell lymphoblastic lymphoma |
| Q40957292 | Prognostic impact of persistent cytogenetic abnormalities at complete remission in adult patients with acute lymphoblastic leukemia |
| Q46477192 | Prognostic impact of pretreatment cytogenetics in adult Philadelphia chromosome-negative acute lymphoblastic leukemia in the era of minimal residual disease |
| Q34146996 | Prognostic significance of CD20 expression in adults with de novo precursor B-lineage acute lymphoblastic leukemia |
| Q46176860 | Prognostic significance of day 14 bone marrow evaluation in adults with Philadelphia chromosome-negative acute lymphoblastic leukemia |
| Q89477006 | Prognostic significance of serum progranulin level in de novo adult acute lymphoblastic leukemia patients |
| Q80094670 | Proportion of long-term event-free survivors and lifetime of adult patients not cured after a standard acute lymphoblastic leukemia therapeutic program: adult acute lymphoblastic leukemia-94 trial |
| Q30667328 | Prospective BCR-ABL analysis by polymerase chain reaction (RT-PCR) in adult acute B-lineage lymphoblastic leukemia: reliability of RT-nested-PCR and comparison to cytogenetic data. |
| Q40509997 | Pseudomembranous colitis presenting as acute colonic obstruction without diarrhea in a patient with gastric Burkitt lymphoma |
| Q36833001 | Rare oral cavity presentation of a B-cell lymphoblastic lymphoma. A case report and review of the literature |
| Q89286746 | Recent Advances in the Biology and Treatment of T Cell Acute Lymphoblastic Leukemia |
| Q89870947 | Recent Advances in the Management of Acute Lymphoblastic Leukaemia |
| Q92276422 | Recent advances in the biology and treatment of B-cell acute lymphoblastic leukemia |
| Q34038573 | Recent approaches in acute lymphoblastic leukemia in adults |
| Q44235075 | Recurrent palmar-plantar erythrodysaesthesia following high-dose cytarabine treatment for acute lymphoblastic leukemia |
| Q45325253 | Reduced-intensity allogeneic stem cell transplantation for patients aged 50 years or older with B-cell ALL in remission: a retrospective study by the Adult ALL Working Group of the Japan Society for Hematopoietic Cell Transplantation. |
| Q46013511 | Reduced-intensity conditioning allogeneic stem cell transplantation is a potential therapeutic approach for adults with high-risk acute lymphoblastic leukemia in remission: results of a prospective phase 2 study. |
| Q37482624 | Reduced-intensity conditioning followed by peripheral blood stem cell transplantation for adult patients with high-risk acute lymphoblastic leukemia |
| Q36149287 | Regulation of HIF-1α signaling and chemoresistance in acute lymphocytic leukemia under hypoxic conditions of the bone marrow microenvironment |
| Q37116917 | Residual DNA methylation at remission is prognostic in adult Philadelphia chromosome-negative acute lymphocytic leukemia |
| Q40951508 | Retrospective analysis of adult patients with acute lymphoblastic leukemia undergoing allogeneic hematopoietic cell transplantation: A multicenter experience of daily practice. |
| Q37695157 | Risk-Benefit Analysis of Pediatric-Inspired Versus Hyperfractionated Cyclophosphamide, Vincristine, Doxorubicin, and Dexamethasone Protocols for Acute Lymphoblastic Leukemia in Adolescents and Young Adults |
| Q36405044 | Role of cytokines in the treatment of acute leukemias: a review |
| Q38947537 | SNP Array in Hematopoietic Neoplasms: A Review |
| Q36438540 | Safe Implementation of Computerized Provider Order Entry for Adult Oncology |
| Q34345218 | Safety and clinical activity of 5-aza-2'-deoxycytidine (decitabine) with or without Hyper-CVAD in relapsed/refractory acute lymphocytic leukaemia |
| Q34186583 | Salvage therapy for refractory or relapsed acute lymphocytic leukemia |
| Q44117877 | Schedule-dependent synergism and antagonism between methotrexate and cytarabine against human leukemia cell lines in vitro. |
| Q35030141 | Serum peptidomic profiling identifies a minimal residual disease detection and prognostic biomarker for patients with acute leukemia |
| Q77324145 | Shift of immunoglobulin phenotypes in B-cell precursor cell lines |
| Q44047918 | Signals mediated by FcgammaRIIA suppress the growth of B-lineage acute lymphoblastic leukemia cells |
| Q40396529 | Significance of recurrence of minimal residual disease detected by multi-parameter flow cytometry in patients with acute lymphoblastic leukemia in morphological remission |
| Q51886360 | Spinal cord compression in an adolescent with relapsed B-precursor acute lymphoblastic leukemia and mental neuropathy. |
| Q37358325 | Splenic rupture, secondary to G-CSF use for chemotherapy induced neutropenia: a case report and review of literature. |
| Q39016544 | Strategies to avoid treatment-induced lineage crisis in advanced prostate cancer |
| Q55406123 | Survival analysis of adult patients with ALL in Mexico City: first report from the Acute Leukemia Workgroup (ALWG) (GTLA). |
| Q91915097 | Survival in adult acute lymphoblastic leukaemia (ALL): A report from the Swedish ALL Registry |
| Q40411469 | Survival predictors of Burkitt's lymphoma in children, adults and elderly in the United States during 2000-2013. |
| Q37255378 | Symptom burden and supportive care in patients with acute leukemia |
| Q37267228 | The 8p11 myeloproliferative syndrome: review of literature and an illustrative case report. |
| Q38759431 | The Approach to Acute Lymphoblastic Leukemia in Older Patients: Conventional Treatments and Emerging Therapies |
| Q52739815 | The First Case of Non-leukemic Sarcoma Composed of Mixed-phenotype Acute Leukemia, B/myeloid, Not Otherwise Specified. |
| Q83996560 | The Hyper-CVAD chemotherapy regimen has an adverse long-term impact on the ability to mobilize peripheral blood stem cells, which can be readily circumvented by using the early cycles for mobilization |
| Q44047927 | The antifungal antibiotic clotrimazole alters calcium homeostasis of leukemic lymphoblasts and induces apoptosis |
| Q35543165 | The biology and therapy of adult acute lymphoblastic leukemia |
| Q38055656 | The coagulopathy and thrombotic risk associated with L-asparaginase treatment in adults with acute lymphoblastic leukaemia |
| Q34123874 | The hyper-CVAD regimen in adult acute lymphocytic leukemia |
| Q47304820 | The role of allogeneic bone marrow transplantation in adult patients below the age of 55 years with acute lymphoblastic leukemia in first complete remission: a donor vs no donor comparison. |
| Q43935093 | The role of high-dose cytarabine in induction therapy for adult ALL. |
| Q44098564 | The role of local radiation therapy for mediastinal disease in adults with T-cell lymphoblastic lymphoma |
| Q38096307 | The treatment of adolescents and young adults with acute lymphoblastic leukemia |
| Q56378380 | Therapeutic Targeting of mTOR in T-Cell Acute Lymphoblastic Leukemia: An Update |
| Q42943448 | Therapeutic alternatives to native L-asparaginase in the treatment of adult acute lymphoblastic leukemia |
| Q37255373 | Traumatic stress in acute leukemia |
| Q27000078 | Treating relapsed or refractory Philadelphia chromosome-negative acute lymphoblastic leukemia: liposome-encapsulated vincristine |
| Q47774455 | Treatment of Older Patients with Acute Lymphoblastic Leukaemia |
| Q40584073 | Treatment of Philadelphia chromosome-positive chronic myelogenous leukemia with weekly polyethylene glycol formulation of interferon-alpha-2b and low-dose cytosine arabinoside |
| Q39206217 | Treatment of Young Adults with Acute Lymphoblastic Leukemia |
| Q38787763 | Treatment of older patients with acute lymphoblastic leukemia. |
| Q35755000 | Treatment of refractory/relapsed adult acute lymphoblastic leukemia with bortezomib-based chemotherapy |
| Q90606756 | Treatment of young adults with Philadelphia-negative acute lymphoblastic leukemia and lymphoblastic lymphoma: Hyper-CVAD vs. pediatric-inspired regimens |
| Q80218913 | Treatment outcome in young adults and children >10 years of age with acute lymphoblastic leukemia in Sweden: a comparison between a pediatric protocol and an adult protocol |
| Q43175147 | Tyrosine kinase inhibitors in BCR-ABL positive acute lymphoblastic leukemia |
| Q45112745 | Unexpected response of hormone-refractory prostate cancer to treatment with an antileukemic chemotherapy regimen |
| Q46112355 | Unrelated SCT induces long-term remission in patients with blastic plasmacytoid dendritic cell neoplasm |
| Q28540672 | mTOR inhibition by everolimus in childhood acute lymphoblastic leukemia induces caspase-independent cell death |
Search more.